It should be noted that a single treatment of DBPR114 is a multi-kinase inhibitor targeted for AML cell line through the FLT3 pathway, and the low-level anti-proliferative activity was detected in an FLT3-negative leukemia cell line [7]. The gene discussed is FLT3; the disease is acute myeloid leukemia.